After long delay following patient death, FDA lifts trial hold on Advaxis/AstraZeneca combo
The FDA has lifted its months-long clinical hold on an Advaxis combo therapy — first brought on by a patient death in its Phase I/II trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
